Key clinical point: First-line bevacizumab (BEV) is more effective than cetuximab or panitumumab (CET/PAN) against right-sided RAS wild-type (WT) metastatic colorectal cancer (mCRC), but comparably effective against left-sided RAS WT mCRC.
Major finding: Patients who received BEV vs CET/PAN had a significantly longer overall survival (hazard ratio [HR] 0.52; 95% CI 0.28-0.96) in the right-sided group, but similar overall survival in the left-sided group (HR 0.78; 95% CI 0.58-1.07).
Study details: This real-world multicenter retrospective study propensity score-matched patients with right-sided (n = 110) and left-sided (n = 450) RAS WT mCRC who received first-line treatment with BEV or CET/PAN plus fluoropyrimidine-based doublet chemotherapy (oxaliplatin or irinotecan).
Disclosures: The study received no specific funding. Some authors declared receiving grants, personal fees, honoraria for lecture and advisory roles, or research funding from various sources.
Source: Ito T et al. Primary tumor location as a predictor of survival in patients with RAS wild-type colorectal cancer who receive molecularly targeted drugs as first-line therapy: A multicenter real-world observational study by the Japanese Society for Cancer of the Colon and Rectum. Int J Clin Oncol. 2022 (Jul 21). Doi: 10.1007/s10147-022-02208-7